Additionally, the frequencies of Pro homozygosity was higher in the patients than in the controls among all three sample sets (sample set 1, 20.93 vs. 17.33%; sample set 2, 24.47 vs. 18.31%, merged samples, 22.42 vs. 17.57%); thereby, the genotype Pro/Pro was viewed as risk allele, multivariate logistic regression was preceded to investigate the possible effect of p53 codon 72 polymorphism in bladder cancer incidence with age and gender adjusted. This evidence concerns the gene TP53 and urinary bladder carcinoma.